The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okano, F.
Right arrow Articles by Engleman, E. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okano, F.
Right arrow Articles by Engleman, E. G.
The Journal of Immunology, 2005, 174: 2645-2652.
Copyright © 2005 by The American Association of Immunologists

In Vivo Manipulation of Dendritic Cells Overcomes Tolerance to Unmodified Tumor-Associated Self Antigens and Induces Potent Antitumor Immunity1

Fumiyoshi Okano2,*, Miriam Merad3,*, Katsuyoshi Furumoto4,* and Edgar G. Engleman5,*

* Department of Pathology, Stanford University School of Medicine, Palo Alto, CA 94304

Most tumor-associated Ags are self proteins that fail to elicit a T cell response as a consequence of immune tolerance. Dendritic cells (DCs) generated ex vivo have been used to break tolerance against such self Ags; however, in vitro manipulation of DCs is cumbersome and difficult to control, resulting in vaccines of variable potency. To address this problem we developed a method for loading and activating DCs, in situ, by first directing sufficient numbers of DCs to peripheral tissues using Flt3 ligand and then delivering a tumor-associated Ag and oligonucleotide containing unmethylated CG motifs to these tissues. In this study, we show in three different tumor models that this method can overcome tolerance and induce effective antitumor immunity. Vaccination resulted in the generation of CD8+ T and NK cell effectors that mediated durable tumor responses without attacking normal tissues. These findings demonstrate that unmodified tumor-associated self Ags can be targeted to DCs in vivo to induce potent systemic antitumor immunity.




This article has been cited by other articles:


Home page
J. Immunol.Home page
A. Filatenkov, A. M. S. Muller, W. W.-L. Tseng, S. Dejbakhsh-Jones, D. Winer, R. Luong, J. A. Shizuru, E. G. Engleman, and S. Strober
Ineffective Vaccination against Solid Tumors Can Be Enhanced by Hematopoietic Cell Transplantation
J. Immunol., December 1, 2009; 183(11): 7196 - 7203.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Ramakrishna, N. Woller, B. Mundt, S. Knocke, E. Gurlevik, M. Saborowski, N. Malek, M. P. Manns, T. Wirth, F. Kuhnel, et al.
Antitumoral Immune Response by Recruitment and Expansion of Dendritic Cells in Tumors Infected with Telomerase-Dependent Oncolytic Viruses
Cancer Res., February 15, 2009; 69(4): 1448 - 1458.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. C. Miller, Y. Ma, J. Bian, K. C. F. Sheehan, J. F. Zachary, J. H. Weis, R. D. Schreiber, and J. J. Weis
A Critical Role for Type I IFN in Arthritis Development following Borrelia burgdorferi Infection of Mice
J. Immunol., December 15, 2008; 181(12): 8492 - 8503.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
S. Mariotti, V. Sargentini, C. Marcantonio, E. Todero, R. Teloni, M. C. Gagliardi, A. R. Ciccaglione, and R. Nisini
T-cell-mediated and antigen-dependent differentiation of human monocyte into different dendritic cell subsets: a feedback control of Th1/Th2 responses
FASEB J, September 1, 2008; 22(9): 3370 - 3379.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Gorczynski, I. Khatri, L. Lee, and I. Boudakov
An Interaction between CD200 and Monoclonal Antibody Agonists to CD200R2 in Development of Dendritic Cells That Preferentially Induce Populations of CD4+CD25+ T Regulatory Cells
J. Immunol., May 1, 2008; 180(9): 5946 - 5955.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
Y. Zhang, D. Wakita, K. Chamoto, Y. Narita, N. Matsubara, H. Kitamura, and T. Nishimura
Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs
Int. Immunol., February 1, 2007; 19(2): 151 - 161.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Schirmbeck, P. Riedl, M. Kupferschmitt, U. Wegenka, H. Hauser, J. Rice, A. Kroger, and J. Reimann
Priming Protective CD8 T Cell Immunity by DNA Vaccines Encoding Chimeric, Stress Protein-Capturing Tumor-Associated Antigen
J. Immunol., August 1, 2006; 177(3): 1534 - 1542.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. M. Ryan and T. D. Schell
Accumulation of CD8+ T Cells in Advanced-Stage Tumors and Delay of Disease Progression following Secondary Immunization against an Immunorecessive Epitope
J. Immunol., July 1, 2006; 177(1): 255 - 267.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
D. Wakita, K. Chamoto, Y. Zhang, Y. Narita, D. Noguchi, H. Ohnishi, T. Iguchi, T. Sakai, H. Ikeda, and T. Nishimura
An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen
Int. Immunol., March 1, 2006; 18(3): 425 - 434.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Chamoto, D. Wakita, Y. Narita, Y. Zhang, D. Noguchi, H. Ohnishi, T. Iguchi, T. Sakai, H. Ikeda, and T. Nishimura
An Essential Role of Antigen-Presenting Cell/T-Helper Type 1 Cell-Cell Interactions in Draining Lymph Node during Complete Eradication of Class II-Negative Tumor Tissue by T-Helper Type 1 Cell Therapy
Cancer Res., February 1, 2006; 66(3): 1809 - 1817.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
I. N. Buhtoiarov, H. D. Lum, G. Berke, P. M. Sondel, and A. L. Rakhmilevich
Synergistic Activation of Macrophages via CD40 and TLR9 Results in T Cell Independent Antitumor Effects
J. Immunol., January 1, 2006; 176(1): 309 - 318.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. J. Tacken, I. J. M. de Vries, K. Gijzen, B. Joosten, D. Wu, R. P. Rother, S. J. Faas, C. J. A. Punt, R. Torensma, G. J. Adema, et al.
Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody
Blood, August 15, 2005; 106(4): 1278 - 1285.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.